Marcela Vieira

Biographic Data

ID7989850
NAMEMarcela Vieira
GIVEN NAMESMarcela
FAMILY NAMEVieira
SIGNATUREVIEIRA M
AFFILIATIONSGlobal Health Centre
ORCID0000-0002-8819-4676
VERIFIEDYes
TOTAL WORKS6
TOTAL CITATIONS7
WORKS AS AUTHOR6
WORKS AS EDITOR0
FIRST PUBLICATION YEAR2008
LATEST PUBLICATION YEAR2026
H-INDEX1

  • Orchestrating faster access to products of non-profit R&D

    Open AccessSuerie Moon, Marcela Vieira et al.ARTICLEBMJ Global Health2026

    INTRODUCTION: Non-profit product development partnerships (PDPs) have succeeded in bringing nearly 80 new drugs, vaccines and diagnostics for neglected diseases through regulatory approval, but arrangements to ensure they reach patients are unclear since the usual commercial incentives do not apply. We conducted a case study of how unusually fast access was achieved to a new treatment regimen for drug-resistant tuberculosis (DR-TB) developed by t…

  • Beyond resistance

    Open AccessIulia Slovenski, Adrián Alonso Ruiz et al.ARTICLEHumanities and Social Sciences…2025

    Accelerating the development, equitable access to, and stewardship of new antibiotics is critical to protect public health and address antimicrobial resistance (AMR). To understand and assess how the current antibiotics innovation sub-system – or ‘niche’ – addresses this task, we reviewed the literature, compiled and analyzed a database of 211 antibiotic developers, and conducted 10 stakeholder interviews. We found that the mainstream market-driv…

  • The 30-year evolution of oral cholera vaccines

    Open AccessKaitlin Large, Adrián Alonso Ruiz et al.ARTICLEPLOS Global Public Health2025

    Cholera outbreaks have been rapidly increasing around the world. While long-term cholera prevention and control measures rely on improvements in water, sanitation, and hygiene, oral cholera vaccines (OCVs) are used for prevention and control in the short-to-medium term. OCVs lack the market incentives available in other more profitable disease areas. The development of OCVs was made possible through an alternative innovation model, which sustaine…

  • Developing globally-accessible medicines for pandemic preparedness

    Open AccessIulia Slovenski, Yiqi Liu et al.ARTICLEGlobal Public Health2025

    Recent infectious disease crises (e.g. COVID-19, Ebola, mpox) show that the mainstream market-driven innovation model cannot ensure both rapid innovation and equitable global access to vaccines, drugs, and diagnostics critical for pandemic preparedness and response. Alternative models that may better address global access needs exist, but analysis of their merits is limited. We analysed the pharmaceutical innovation 'niche' for pandemic products …

  • Which roads lead to access? A global landscape of six Covid-19 vaccine innovation models

    Open AccessAdrián Alonso Ruiz, Anna Bezruki et al.ARTICLEGlobalization and Health2024

    BACKGROUND: Unequal and inequitable access to Covid-19 vaccines in low- and middle-income countries (L&MICs) was a major political, ethical and public health failure in the pandemic. However, vaccine developers' practices were not monolithic, but rather, took diverse approaches to supplying different countries, with important implications for global access. RESULTS: Using data on R&D investments, regulatory approvals, manufacturing and purchase a…

  • Acesso a medicamentos e propriedade intelectual no Brasil

    Open AccessGabriela Costa Chaves, Marcela Fogaça Vieira et al.ARTICLESur - Revista Internacional de…2008Cited by: 7References: 3

    O presente artigo aborda o sistema de proteção à propriedade industrial vigente no Brasil e sua relação com a política de acesso universal a medicamentos para tratamento da AIDS. Ainda, apresenta as principais estratégias de atuação de um grupo da sociedade civil brasileira - GTPI/REBRIP - em relação aos principais problemas e desafios identificados